The 3C Study: Alemtuzumab may reduce acute rejection following kidney transplant
1. Alemtuzumab induction treatment significantly reduced events of biopsy-proven acute rejection (BPAR) when compared with standard basiliximab-based therapy (BBT). 2....

![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://www.2minutemedicine.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-350x250.jpg)







